(Q40239051)

English

Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis

scientific article published on March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

0 references

liver cirrhosis

0 references

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

object named as

Nezam Afdhal

3

0 references

object named as

Robert G Gish

6

0 references

K. Rajender Reddy

7

object named as

K Rajender Reddy

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

Paul J Pockros

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Lennox Jeffers

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Zachary D Goodman

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

David Nelson

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Robert Reindollar

8

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Maribel Rodriguez-Torres

9

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sarah Sullivan

10

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Lawrence M Blatt

11

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sima Faris-Young

12

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

1 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

569-578

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

21 January 2018

Sampling variability of liver fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

21 January 2018

Evaluation of fibrosis and hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Transforming growth factor beta in tissue fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased hepatitis C virus (HCV)-specific CD4+CD25 + regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilot study of interferon gamma for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21561

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.21561

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40239051&oldid=1889746286"